Tanaka Yukinori, Izawa Masumi, Hiraga Yoshikazu, Misaki Yuya, Watanabe Tomoko, Ochi Kozo
Department of Life Sciences, Hiroshima Institute of Technology, Saeki-ku, Hiroshima, 731-5193, Japan.
Appl Microbiol Biotechnol. 2017 Jun;101(11):4417-4431. doi: 10.1007/s00253-017-8216-6. Epub 2017 Mar 14.
Although transcriptional activation of pathwayspecific positive regulatory genes and/or biosynthetic genes is primarily important for enhancing secondary metabolite production, reinforcement of substrate supply, as represented by primary metabolites, is also effective. For example, partial inhibition of fatty acid synthesis with ARC2 (an analog of triclosan) was found to enhance polyketide antibiotic production. Here, we demonstrate that this approach is effective even for industrial high-producing strains, for example enhancing salinomycin production by 40%, reaching 30.4 g/l of salinomycin in an industrial Streptomyces albus strain. We also hypothesized that a similar approach would be applicable to another important antibiotic group, nonribosomal peptide (NRP) antibiotics. We therefore attempted to partially inhibit protein synthesis by using ribosome-targeting drugs at subinhibitory concentrations (1/50∼1/2 of MICs), which may result in the preferential recruitment of intracellular amino acids to the biosynthesis of NRP antibiotics rather than to protein synthesis. Among the ribosome-targeting drugs examined, chloramphenicol at subinhibitory concentrations was most effective at enhancing the production by Streptomyces of NRP antibiotics such as actinomycin, calcium-dependent antibiotic (CDA), and piperidamycin, often resulting in an almost 2-fold increase in antibiotic production. Chloramphenicol activated biosynthetic genes at the transcriptional level and increased amino acid pool sizes 1.5- to 6-fold, enhancing the production of actinomycin and CDA. This "metabolic perturbation" approach using subinhibitory concentrations of ribosome-targeting drugs is a rational method of enhancing NRP antibiotic production, being especially effective in transcriptionally activated (e.g., rpoB mutant) strains. Because this approach does not require prior genetic information, it may be widely applicable for enhancing bacterial production of NRP antibiotics and bioactive peptides.
虽然途径特异性正调控基因和/或生物合成基因的转录激活对于提高次级代谢产物产量至关重要,但以初级代谢产物为代表的底物供应增强也很有效。例如,发现用ARC2(三氯生类似物)部分抑制脂肪酸合成可提高聚酮类抗生素的产量。在此,我们证明这种方法对工业高产菌株也有效,例如将盐霉素产量提高40%,在工业白色链霉菌菌株中达到30.4克/升的盐霉素。我们还推测类似方法适用于另一重要抗生素组,即非核糖体肽(NRP)抗生素。因此,我们试图使用亚抑制浓度(最低抑菌浓度的1/50至1/2)的核糖体靶向药物部分抑制蛋白质合成,这可能导致细胞内氨基酸优先用于NRP抗生素的生物合成而非蛋白质合成。在所检测的核糖体靶向药物中,亚抑制浓度的氯霉素在提高链霉菌产生NRP抗生素如放线菌素、钙依赖性抗生素(CDA)和哌啶霉素的产量方面最有效,抗生素产量常常几乎增加两倍。氯霉素在转录水平激活生物合成基因,并使氨基酸库大小增加1.5至6倍,从而提高放线菌素和CDA的产量。这种使用亚抑制浓度核糖体靶向药物的“代谢扰动”方法是提高NRP抗生素产量的合理方法,在转录激活(例如rpoB突变体)菌株中尤其有效。由于这种方法不需要预先的遗传信息,它可能广泛适用于提高细菌产生NRP抗生素和生物活性肽的产量。